Kario, Kazuomi
Nishizawa, Masafumi
Kato, Mitsutoshi
Ishii, Hajime
Uchiyama, Kazuaki
Nagai, Michiaki
Takahashi, Nobuo
Asakura, Taro
Shiraiwa, Toshihiko
Yoshida, Tetsuro
Kaneshiro, Mizuki
Taguchi, Takashi
Shiosakai, Kazuhito
Sugimoto, Kotaro
Article History
Received: 30 November 2022
Revised: 3 April 2023
Accepted: 4 April 2023
First Online: 12 May 2023
Compliance with ethical standards
:
: KK has received research funding from A&D Co., Ltd., Otsuka Holdings Co., Ltd., OMRON HEALTHCARE Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Taisho Pharma Co., Ltd., Teijin Pharma Ltd., Fukuda Lifetech Co., Ltd., and Fukuda Denshi Co., Ltd.; scholarships or donations from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Mochida Pharmaceutical Co., Ltd; and is an editorial board member of Hypertension Research; however, Hypertension Research automatically selects a Deputy Editor when papers from members of the editorial board are submitted, and he is completely independent of the review process. M Nishizawa has received honoraria and fees for promotional materials from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Otsuka Pharmaceutical Co., Ltd. TY has received honoraria and fees for promotional materials from Daiichi Sankyo Co., Ltd. TT, K Shiosakai, and K Sugimoto are employees of Daiichi Sankyo Co., Ltd. The other authors have no conflict of interest to disclose.